Prediction of response to anti-EGFR antibodies in metastatic colorectal cancer: looking beyond EGFR inhibition

about

Prediction of response to anti-EGFR antibodies in metastatic colorectal cancer: looking beyond EGFR inhibition

Item

http://www.wikidata.org/entity/Q36516784

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Prediction of response to anti ...... looking beyond EGFR inhibition

@ast

Prediction of response to anti ...... looking beyond EGFR inhibition

@en

type

Item

label

Prediction of response to anti ...... looking beyond EGFR inhibition

@ast

Prediction of response to anti ...... looking beyond EGFR inhibition

@en

prefLabel

Prediction of response to anti ...... looking beyond EGFR inhibition

@ast

Prediction of response to anti ...... looking beyond EGFR inhibition

@en

P1476

Prediction of response to anti ...... looking beyond EGFR inhibition

@en

P2093

Alessandro Ottaiano

http://www.w3.org/2001/XMLSchema#string

Maurizio Capuozzo

http://www.w3.org/2001/XMLSchema#string

Piera Maiolino

http://www.w3.org/2001/XMLSchema#string

Rosario V Iaffaioli

http://www.w3.org/2001/XMLSchema#string

Valentina De Angelis

http://www.w3.org/2001/XMLSchema#string

P2860

A functional variant of Fcgamma receptor IIIA is associated with rheumatoid arthritis in individuals who are positive for anti-glucose-6-phosphate isomerase antibodies.

KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer.

The evolving role of monoclonal antibodies in colorectal cancer: early presumptions and impact on clinical trial development.

Direct and immune mediated antibody targeting of ERBB receptors in a colorectal cancer cell-line panel

Fc gamma receptor IIIa polymorphisms in advanced colorectal cancer patients correlated with response to anti-EGFR antibodies and clinical outcome.

Diversity of human immune system multigene families and its implication in the genetic background of rheumatic diseases.

Combination strategies to enhance antitumor ADCC.

Activation of tumor-promoting type 2 macrophages by EGFR-targeting antibody cetuximab.

FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.

Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.

P304

409

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.3389/FIMMU.2012.00409

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Stefania Scala

Guglielmo Nasti

P577

2012-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

234125049

http://www.w3.org/2001/XMLSchema#string

P698

23316197

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

3539668

http://www.w3.org/2001/XMLSchema#string